Decades of work by a series of researchers has led to a groundbreaking drug, innovative patents, and the launch of a new startup.
A scientific journey decades in the making at Duke University has discovered a novel antibiotic approach to combat gram-negative bacteria, including Salmonella, Pseudomonas, and E. coli, which are often responsible for urinary tract infections (UTIs). The synthetic molecule works fast and is durable in animal tests.
“If you disrupt the synthesis of the bacterial outer membrane, the bacteria cannot survive without it,” said lead investigator Pei Zhou, a professor of biochemistry at the Duke School of Medicine. “Our compound is very good and very potent.”
And it works fast. “LPC-233 can reduce bacterial viability by 100,000-fold within four hours,” Zhou said.
The compound is also tenacious enough to survive all the way to the urinary tract after oral administration, which may make it a vital tool against stubborn urinary tract infections (UTIs).
In animal studies, the compound was successful when administered orally and intravenously or injected into the abdomen. In one experiment, mice given what should have been a fatal dose of multidrug-resistant bacteria were rescued by the new compound.
The search for this compound took decades because of the specificity and safety required of the synthetic molecule.
Zhou credits his late colleague, former Duke Biochemistry Chair Christian Raetz, for starting the search decades ago. “He spent his entire career working on this pathway,” Zhou said. “Dr. Raetz proposed a conceptual blueprint for this pathway in the 1980s, and it took him over two decades to identify all of the players,” Zhou said.
The new drug’s target is an enzyme called LpxC which is the second enzyme in the “Raetz pathway” and is essential to making the outer membrane lipid in gram-negative bacteria.
Raetz joined Duke as the chairman of biochemistry in 1993 after his work on this pathway at Merck & Co. had failed to produce a successful clinical candidate. The Merck antibiotic worked, but only against E. coli, so it wasn’t commercially viable and the pharmaceutical company dropped it.
“He actually recruited me to Duke to work on this enzyme, initially just from the structural biology perspective,” said Zhou, who came to Duke in 2001.
Zhou and Raetz had solved the structure of the LpxC enzyme and revealed molecular details of a few potential inhibitors. “We realized that we could tweak the compound to make it better,” Zhou said. Since then, Zhou has been working with his colleague, Duke Chemistry professor Eric Toone, to make more potent LpxC inhibitors.
The first human trial of LpxC inhibitors had failed because of cardiovascular toxicity. The focus of the Duke group’s subsequent work was to avoid cardiovascular effects while maintaining the potency of the compound.
They worked on more than 200 different versions of the enzyme inhibitor, always searching for better safety and more potency. Other compounds worked to varying degrees, but compound number 233 was the winner.
LPC-233 fits a binding spot on the LpxC enzyme and prevents it from doing its work. “It fits in the right way to inhibit formation of the lipid,” Zhou said. “We’re jamming the system.”
Adding to its durability, the compound works by a remarkable two-step process, Zhou said. After the initial binding to LpxC, the enzyme-inhibitor complex changes its shape somewhat to become an even more stable complex.
The lifetime of the inhibitor binding in this more stable complex is longer than the lifetime of the bacteria. “We think that contributes to the potency, as it has a semi-permanent effect on the enzyme,” he said. “Even after the unbound drug is metabolized by the body, the enzyme is still inhibited due to the extremely slow inhibitor dissociation process,” Zhou said.
There are multiple patents being filed on the series of compounds, and Toone and Zhou have co-founded a company called Valanbio Therapeutics, Inc. which will be looking for partners to bring LPC-233 through phase 1 clinical trials to assess safety and efficacy in humans.
“All of these studies were done in animals,” Zhou said. “Ultimately the cardiovascular safety needs to be tested in humans.”
Reference: “Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens” by Jinshi Zhao, C. Skyler Cochrane, Javaria Najeeb, David Gooden, Carly Sciandra, Ping Fan, Nadine Lemaitre, Kate Newns, Robert A. Nicholas, Ziqiang Guan, Joshua T. Thaden, Vance G. Fowler, Ivan Spasojevic, Florent Sebbane, Eric J. Toone, Clayton Duncan, Richard Gammans and Pei Zhou, 9 August 2023, Science Translational Medicine.
DOI: 10.1126/scitranslmed.adf5668
Large scale synthesis of LPC-233 was first accomplished by David Gooden at the Duke Small Molecule Synthesis Facility. Vance Fowler and Joshua Thaden (Duke School of Medicine), Ziqiang Guan (Biochemistry), and Ivan Spasojevic (Duke PK/PD Core) helped with in vivo studies, mass spectrometry, and pharmacokinetics analysis.
This work was supported by grants from National Institutes of Health (R01 GM115355, AI094475, AI152896, AI148366), the North Carolina Biotechnology Center (2016-TEG-1501), and a National Cancer Institute Comprehensive Cancer Center Core Grant (P30CA014236).

News
Tiny robots made from human cells heal damaged tissue
The ‘anthrobots’ were able to repair a scratch in a layer of neurons in the lab. Scientists have developed tiny robots made of human cells that are able to repair damaged neural tissue1. The [...]
Antimicrobial Resistance – A Global Concern
Key facts Antimicrobial resistance (AMR) is one of the top global public health and development threats. It is estimated that bacterial AMR was directly responsible for 1.27 million global deaths in 2019 and contributed to [...]
Advancing Pancreatic Cancer Treatment with Nanoparticle-Based Chemotherapy
Pancreatic cancer, a particularly lethal form of cancer and the fourth leading cause of cancer-related deaths in the western world, often remains undiagnosed until its advanced stages due to a lack of early symptoms. [...]
The ‘jigglings and wigglings of atoms’ reveal key aspects of COVID-19 virulence evolution
Richard Feynman famously stated, "Everything that living things do can be understood in terms of the jigglings and wigglings of atoms." This week, Nature Nanotechnology features a study that sheds new light on the evolution of the coronavirus [...]
AI system self-organizes to develop features of brains of complex organisms
Cambridge scientists have shown that placing physical constraints on an artificially-intelligent system—in much the same way that the human brain has to develop and operate within physical and biological constraints—allows it to develop features [...]
How Blind People Recognize Faces via Sound
Summary: A new study reveals that people who are blind can recognize faces using auditory patterns processed by the fusiform face area, a brain region crucial for face processing in sighted individuals. The study employed [...]
Treating tumors with engineered dendritic cells
Cancer biologists at EPFL, UNIGE, and the German Cancer Research Center (Heidelberg) have developed a novel immunotherapy that does not require knowledge of a tumor's antigenic makeup. The new results may pave the way [...]
Networking nano-biosensors for wireless communication in the blood
Biological computing machines, such as micro and nano-implants that can collect important information inside the human body, are transforming medicine. Yet, networking them for communication has proven challenging. Now, a global team, including EPFL [...]
Popular Hospital Disinfectant Ineffective Against Common Superbug
Research conducted during World Antimicrobial Awareness Week examines the effects of employing suggested chlorine-based chemicals to combat Clostridioides difficile, the leading cause of antibiotic-related illness in healthcare environments worldwide. A recent study reveals that a [...]
Subjectivity and the Evolution of AI Philosophy
An Historical Overview of the Philosophy of Artificial Intelligence by Anton Vokrug Many famous people in the philosophy of technology have tried to comprehend the essence of technology and link it to society and human [...]
How Lockdowns Shaped the Virus: AI Uncovers COVID-19’s Evolutionary Secrets
A new research study shows that human behavior, like lockdowns, influences the evolution of COVID-19, leading to strains that are more transmissible earlier in their lifecycle. Using artificial intelligence technology and mathematical modeling, a research [...]
Groundbreaking therapy approved: chances of cure for 7000 diseases:
Hereditary diseases are usually not curable. Now, however, an epochal turning point is taking place in medicine: For the first time ever, a therapy with the CRISPR/Cas9 gene scissors has received approval. According to [...]
Uncovering the Genetic Mystery: Why Some Never Show COVID-19 Symptoms
New study shows that common genetic variation among people is responsible for mediating SARS-CoV-2 asymptomatic infection. Have you ever wondered why some people never became sick from COVID-19? A study published recently in the journal Nature shows that common [...]
AI maps tumor geography for tailored treatments
Researchers have integrated AI approaches from satellite mapping and community ecology to develop a tool to interpret data obtained from tumor tissue imaging, with the aim of implementing a more individualized approach to cancer care. [...]
Lung cancer cells’ ‘memories’ suggest new strategy for improving treatment
A new understanding of lung cancer cells' "memories" suggests a new strategy for improving treatment, Memorial Sloan Kettering Cancer Center (MSK) researchers have found. Research from the lab of cancer biologist Tuomas Tammela, MD, Ph.D. [...]
Artificial sensor similar to a human fingerprint can recognize fine fabric textures
An artificial sensory system that is able to recognize fine textures—such as twill, corduroy and wool—with a high resolution, similar to a human finger, is reported in a Nature Communications paper. The findings may help improve the subtle [...]